Reviewing 6 years of FDA warning letters to healthcare practices (2020-2026) reveals remarkably consistent claim patterns. The FDA cites the same categories of language repeatedly, across specialties and enforcement waves. Understanding these specific patterns is the fastest path to compliance - and to writing marketing that doesn’t land a clinic on the next enforcement list.
Category 1: Disease-treatment claims
1. “Cures [specific disease]”
“Cures arthritis”
“May support joint comfort and function for some patients”
2. “Treats [specific disease]”
“Treats Parkinson's disease”
“(Remove disease-specific treatment claims from public marketing.)”
3. “Heals damaged tissue”
“Heals damaged cartilage and torn ligaments”
“May support the body's tissue response in treated areas”
4. “Prevents [specific disease]”
“Prevents heart disease and stroke”
“Supports overall wellness as part of a comprehensive approach”
5. “Reverses [disease or aging]”
“Reverses aging and chronic fatigue”
“May support cellular metabolism; individual experiences vary”
Category 2: Regulatory status misrepresentation
6. “FDA-approved [HCT/P product]”
“FDA-approved stem cells”
“Performed in an FDA-registered facility using HCT/P materials under the 361 pathway”
7. “FDA-approved [cleared device]”
“FDA-approved laser”
“FDA-cleared for [specific labeled indication]”
8. “FDA-registered” as endorsement
“Treatments performed in our FDA-registered facility”
“Our practice is licensed by [state authority]; treatments follow established clinical protocols”
9. “FDA-approved for [off-label indication]”
“FDA-approved Botox for jawline slimming”
“Neuromodulator treatment for [clinical goal]”
10. “FDA breakthrough designation” misuse
“FDA breakthrough-designated treatment for [condition]”
“Our practice offers [treatment] based on clinical literature; individual candidacy assessed at consultation”
Category 3: Efficacy and safety absolutes
11. “Guaranteed results”
“Guaranteed results or your money back”
“Most of our patients report high satisfaction; individual results vary”
12. “100% effective”
“100% effective at [outcome]”
“Clinical studies of [treatment] in [population] showed [specific finding]”
13. “No side effects”
“No side effects”
“Most patients tolerate treatment well; potential side effects are reviewed during consultation”
14. “Completely safe”
“Completely safe, risk-free treatment”
“Treatment has a favorable safety profile in appropriate candidates; specific risks reviewed at consultation”
15. “Works for everyone”
“Works for every patient”
“Appropriate for many patients; candidacy assessed individually”
Category 4: Unsubstantiated efficacy framing
16. “Clinically proven” without citation
“Clinically proven to [outcome]”
“A [year] clinical study of [protocol] in [population] showed [specific finding] (citation)”
17. “Proven to [outcome]”
“Proven to restore joint function”
“Some patients report improvement in comfort and function in the treated area”
18. “Scientifically backed”
“Scientifically backed treatment”
“Our protocol is informed by current clinical literature on [broader field]”
19. “Research shows” without citation
“Research shows our treatment is highly effective”
“[Specific citation with specific finding]”
20. “Breakthrough technology”
“Breakthrough technology that revolutionizes [category]”
“Technology our practice uses for [specific indication] based on [specific training or development]”
Category 5: Claim implication patterns
21. Specific-condition testimonials
“After my stem cell treatment, my MS symptoms disappeared”
“(Retire specific-condition testimonials; use general satisfaction framing instead)”
22. Before/after with disease framing
“Before our treatment: arthritis pain. After: pain-free”
“[Patient initials], 12 weeks post-treatment. Individual results vary; typical outcomes depend on candidacy and adherence”
23. Off-label symptom targeting
“Botox for [specific off-label indication]”
“Neuromodulator treatment for [clinical goal as discussed at consultation]”
24. Systemic-effect claims for local treatments
“Our injection helps with chronic inflammation throughout the body”
“Treatment addresses concerns in the treated area; systemic effects are not the intended therapeutic mechanism”
25. “Natural” as safety endorsement
“Natural treatment with no chemicals or drugs”
“Treatment uses [specific material or process]; safety profile is reviewed at consultation”
Why these specific patterns persist
Several factors explain why the same patterns appear repeatedly:
- Manufacturer-to-clinician marketing materials often use language that translates poorly to consumer contexts.
- Agency creative practices developed in other industries use patterns that don’t work in healthcare.
- Competitive pressure to make confident claims that “everyone else” uses.
- Lack of specific compliance training for marketing staff.
- Educational content that drifts into promotional framing.
Using this analysis
The most practical use: run your current marketing through a review against these 25 categories. Even partial coverage catches most common compliance issues. The specific phrases vary; the categories are remarkably consistent.
FDA enforcement is not arbitrary. The same categories of problematic language appear year after year because they’re the categories that convert the product into an unapproved drug under 201(g), trigger misbranding under 502, or create deceptive-advertising exposure under FTC rules. The rules are stable; compliance practice just has to match them.
Frequently asked questions
How do I know if a phrase falls in one of these categories?
If it names a disease or condition and claims treatment of it, it’s Category 1. If it misrepresents FDA regulatory status, Category 2. If it’s absolute about outcome or safety, Category 3. If it claims evidence without citation, Category 4. If it implies through context what direct statement would, Category 5.
Are some categories more-commonly cited than others?
Category 1 (disease-treatment) and Category 2 (regulatory status) appear most frequently. Categories 3-5 appear across most letters in varying combinations.
Does this analysis cover FTC enforcement too?
Partially. Categories 3-5 overlap substantially with FTC enforcement patterns. FTC-specific patterns (testimonial disclosure, material-connection, review-gating) are covered in our FTC-specific posts.
What about specialty-specific patterns?
Each healthcare specialty has additional patterns layered on these general categories. See our specialty-specific compliance posts for those layers.
How often do new categories emerge?
New patterns emerge as new treatments and marketing formats emerge. Recent additions include AI-generated testimonials, social-media transformation framing, and specific compounded-drug equivalency patterns.
Is there a definitive list of prohibited phrases?
No single definitive list. Categories are more durable than specific phrase lists because the same claim can be phrased many ways. Category-based analysis catches patterns that specific phrase lists miss.